Article
Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Breast cancer research : BCR - 14 Dec 2023
Cheng Han-Fang, Tsai Yi-Fang, Liu Chun-Yu, Hsu Chih-Yi, Lien Pei-Ju, Lin Yen-Shu, Chao Ta-Chung, Lai Jiun-I, Feng Chin-Jung, Chen Yen-Jen, Chen Bo-Fang, Chiu Jen-Hwey, Tseng Ling-Ming, Huang Chi-Cheng
Abstract excerpt
BACKGROUND: The homologous recombination (HR) repair pathway for DNA damage, particularly the BRCA1 and BRCA2 genes, has become a target for cancer therapy, with poly ADP-ribose polymerase (PARP) inhibitors showing significant outcomes in treating germline BRCA1/2 (gBRCA1/2) mutated breast cancer. Recent studies suggest that some patients with somatic BRCA1/2 (sBRCA1/2) mutation or mutations in HR-related genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.